Betekenis en Metodologie van Fundamentele Analise (2025)

Dividendbetalende aandele: opbrengs, risiko, strategie

Balansstaat en inkomstestaat duidelik gemaak 2025

Wat is 'n aandelebeurs? Werking, akteurs, voorbeelde

Aandeelwaardasie 2025: 'n Beginnersgids

Objective Corporation (ASX:OCL) aandeelfundamentele aspekte, oorsig



Objective Corporation is 'n Australiese sagtewaremaatskappy wat in 1987 gestig is en spesialiseer in inhoud- en rekordbestuur- en regulatoriese werkvloeisagteware vir die regering en gereguleerde nywerheidsektore (bv. verdedigingsinstellings, weermag, ens.). Die maatskappy word vandag steeds deur stigter Tony Walls gelei, wat ongeveer 64.81% van die aandele besit deur die TBW Group-houermaatskappy, een van die hoogste stigter

Objective Corporation (ASX:OCL) aandeelfundamentele aspekte, oorsig



Objective Corporation is 'n Australiese sagtewaremaatskappy wat in 1987 gestig is en spesialiseer in inhoud- en rekordbestuur- en regulatoriese werkvloeisagteware vir die regering en gereguleerde nywerheidsektore (bv. verdediging

Objektiewe Korporasie Aandeelanalise – Staat Binne Staat

Wat bevat die aandelemarkverslagafdeling?



Die aandeelprys het bestendig gedaal voor die Computer Modelling Group se 2027 K1-verslag, aangesien die transformasie van die volwasse oliemaatskappy in 'n reeksverkrygingsmaatskappy langer neem as verwag. Daarom verdien dit 'n plek in die afdeling "Verslaggewing van die Effektebeurs", wat altyd 'n opdatering oor fundamentele analise is. Maar waaroor gaan dit alles?



Die kolom is 'n soort kompas vir beleggers wat hulle help om deur die digte datast

Wat bevat die aandelemarkverslagafdeling?



Die aandeelprys het bestendig gedaal voor die Computer Modelling Group se 2027 K1-verslag, aangesien die transformasie van die volwasse oliemaatskappy in 'n reeksverkrygingsmaatskappy langer neem as verwag. Daarom verdien dit 'n plek in die afdeling "Vers

Rekenaarmodelleringsgroep 2027 K1 - Omkeerpunte draai selde?

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

The trust seeks to achieve its investment objective by holding a portfolio of the common stocks that are included in the index (the "Portfolio"), with the weight of each stock in the Portfolio substantially corresponding to the weight of such stock in the index.

FDA launches pilot program that aims to speed the time to first-in-human drug trials

J&J reports phase 2b data on less-frequent lung cancer treatment

J&J/Contineum depression candidate fails in phase 2

Johnson & Johnson (JNJ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Apollo in talks to acquire J&J’s orthopedics unit - Bloomberg

Johnson & Johnson wins CE mark as new ACUVUE contact lens nears Europe launch

Johnson & Johnson (JNJ) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

FDA names acting heads of drug and vaccine units to permanent roles

Insider trades: Nvidia, TSMC, and Johnson & Johnson among notable names

J&J hits all-time high as UBS assumes Buy on transition to growth

Most and least shorted mid- to mega-cap healthcare stocks at the end of August

Johnson & Johnson Replaced $913 Million In Lost Sales With $2.4 Billion In New Ones - But Kept Less Than Half

J&J's Stelara granted approval for pediatric ulcerative colitis

J&J granted China nod for oral psoriasis pill developed with Protagonist

J&J wins FDA label expansion for Imaavy in wAIHA

Johnson & Johnson: Buy IMAAVY Label Expansion First And Continued CAPLYTA Sales Push

Lawmakers ask FDA to scrutinize Chinese trials amid deaths - report

Trump nominates White House adviser Overton as next FDA commissioner

Trump expected to nominate White House aide Heidi Overton as FDA commissioner

President boasts of drug savings with Most Favored Nation policy, TrumpRx

Johnson & Johnson: Quality, But It Doesn't Deserve A Mid-20s Multiple Right Now

SA Asks: What's the outlook for Big Pharma M&A?

'Most Favored Nation' drug pricing would save Medicare more than $200B: AARP

Johnson & Johnson (JNJ) Discusses FDA Authorization and Market Introduction of OTTAVA Robotic Surgical System Transcript

Most and least shorted mid- to mega-cap healthcare stocks at the end of July

July healthcare recap: Regeneron, DexCom shine as Moderna, managed-care stocks retreat

J&J granted FDA priority review for Rybrevant Faspro in head and neck cancer

Johnson & Johnson gets $2.58B option to acquire Sail in vivo CAR-T therapies push

Johnson & Johnson shares fell after six-session winning streak

Johnson & Johnson to pay up to $5.5B to settle talc lawsuits

Operations comments

segment-revenues

Segment Revenues ($M)

geographic-revenues

Geographic Revenues ($M)

Rekeninge betaalbaar

Totale bedryfsbates

Kontant

Kort/huidige langtermynskuld

Klandisiewaarde

Ontasbare bates

Netto tasbare bates

Eiendom, aanleg en toerusting

Netto debiteure

Aandeelhouersbelang

Totale bates

Totale bedryfslaste

Totale laste

Balansstaat

Kapitale uitgawes (TTM)

Bedryfskontantvloei (TTM)

Dividende betaal (TTM)

Vrye kontantvloei (TTM)

Kontantvloei

DGR 10 jare

DGR 15 jare

DGR 3 jare

DGR 5 jare

DGR MR

DGR TTM

EPS groei (5j vorentoe)

EPS groei (5j)

Tyd sedert laaste verandering aangekondig

Dividendgroei

Gemiddelde opbrengs

Opbrengs as % van maksimum opbrengs

Afslag tot gemiddelde opbrengs

Dividend per aandeel

Dividendopbrengs

Uitbetaling frekwensie

Maksimum opbrengs

Minimum opbrengs

Opwaartse potensiaal

Dividend opbrengs - 5j

Gemiddelde tyd tot nuwe hoogtepunt

Gemiddelde daling vanaf hoogtepunt

Maksimum tyd tot nuwe hoogtepunt

Hoogste prysdaling

Datum van hoogste daling

Huidige prysdaling vanaf die hoogste punt van alle tye

Afwaartse potensiaal

CCC status

Jare van groei

EPS (1j vorentoe)

EPS (TTM)

Ex-dividend datum

Kontant opbrengs op belegde kapitaal

Opbrengs op bates

Opbrengs op ekwiteit

Opbrengs op belegde kapitaal

Finansiële opbrengste

Bruto wins (TTM)

Netto inkomste (TTM)

Bedryfsinkomste (TTM)

Inkomste (TTM)

Inkomstestaat

Bruto marge (TTM)

Bedryfsmarge (TTM)

Winsgrens (TTM)

Marges

Gemiddeld

Vorentoe

Uitbetalingverhouding

FCF per aandeel (TTM)

Huidige aandeeltelling

Per aandeel

Huidige opbrengsverspreiding

Opbrengs by 0% (Max)

Opbrengs by 10%

Opbrengs by 100% (Min)

Opbrengs by 20%

Opbrengs by 50% (Mediaan)

Opbrengs by 80

Opbrengs by 90%

Opbrengsverdeling (omgekeerde persentiel) - 5j

Hoogtepunt van alle tye

1j analiseraaming

Beta

Prys by sluiting

Daaglikse hoog

Daaglikse laag

Open

Daaglikse volume

Volgende verdienste datum

Aandele grafiek

EV tot verkope

Prys tot Boekwaarde

Prys tot verkope

Waardering (Verkope/Boekwaarde)

EV tot EBITDA

Agterlopende P/E

Prys tot EBITDA

Prys tot FCF

Prys tot OCF

Waarderingsverhoudings

JNJ

Objektiewe Korporasie Aandeelanalise – Staat Binne Staat

Besigheid insig

Betekenis en Metodologie van Fundamentele Analise (2025)

Segment Revenues ($M)

Geographic Revenues ($M)